Zusammenfassung
Erläutert werden alle relevanten Funktionstests mit ausführlicher Darstellung von Indikationen, Kontraindikationen, Nebenwirkungen, Testvorbereitung, Rahmenbedingungen, konkreten Handlungsanleitung der eigentlichen Testdurchführung sowie der Interpretation der Testergebnisse. Es werden immer konkrete Normbereiche und Cut-off-Werte angegeben, auch für besondere Situationen (Geschlecht, Alter, BMI, Pubertätsphasen, Zyklusphasen, akute Erkrankungen, Medikamente etc.). Ein besonderes Merkmal ist die Betonung der Testvorbereitung, -durchführung und -interpretation sowie des interdisziplinären Charakters. Hormonmissbrauch und Doping spielen auch in der klinischen Routine eine immer größere Rolle. Das Kapitel gibt einen orientierenden Überblick, insbesondere zur Hypoglycaemia factitia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Cryer PE, Axelrod L, Grosman AB et al (2009) Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 94:709
Service FJ (2014) Factitious hypoglycemia. UpToDate online. Wolters Kluwer, Aphen aan den Rijn
Hoizey G, Lamiable D, Trenque T et al (2005) Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem 51:1666
Wang M, Miksa IR (2007) Multi-component plasma quantification of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 856:318
Paroni R, Comuzzi B, Arcelloni C et al (2000) Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Clin Chem 46:1773
Malli D, Gikas E, Vavagiannis A et al (2007) Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. Anal Chim Acta 599:143
Neal JM, Han W (2008) Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia. Endocr Pract 14:1006
Moriyama M, Hayashi N, Ohyabu C et al (2006) Performace evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem 52:1423
Owen WE, Roberts WL et al (2004) Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 50:257
Bowsher RR, Lynch RA, Brown-Augsburger P et al (1999) Sensitive RIA for the specific determination of insulin lispro. Clin Chem 45:104
Andersen L, Jorgensen PN, Jensen LB, Walsh D (2000) A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 33:627
Walfish PG, Feig DS, Bauman WA (1987) Factitious hyperinsulinemic hypoglycemia: confirmation of the diagnosis by a species-specific insulin radioimmunoassay. J Endocrinol Invest 10:601
Barnes KP, Rainbow CR (2013) Update on banned substances 2013. Sport Health 5:442–447
Fitch K (2012) Proscribed drugs at the Olympic games: permitted use and misuse (doping) by athletes. Clin Med 12:257–260
den Broek I van, Blokland M, Nessen MA, Sterk S (2013) Current trends in mass spectrometry of peptides and proteins: application to veterinary and sports-doping control. Mass Spectrom Rev. https://doi.org/10.1002/mas.21419
Bidlingmeier M (2012) New detection methods of growth hormone and growth factors. Endocr Dev Basel, Karger 23:52–59
Wallace JD, Cuneo RC, Bidlginmaier M et al (2001) Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trainded adult males. J Clin Endocrinol Metab 86:1731–1737
Keller A, Wu Z, Kratzsch J et al (2007) Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur J Endocrinol 156:647–653
Bidlingmaier M, Wu Z, Strasburger CJ (2003) Problems with GH doping in sports. J Endocrinol Invest 26:924–931
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Schäffler, A. et al. (2018). Hormonmissbrauch, Doping, Wirkstoffnachweis. In: Schäffler, A. (eds) Funktionsdiagnostik in Endokrinologie, Diabetologie und Stoffwechsel. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55914-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-55914-7_21
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55913-0
Online ISBN: 978-3-662-55914-7
eBook Packages: Medicine (German Language)